Dianthus Therapeutics, Inc.'s revenue has shrunk 32% a year over three years. Revenue growth, 3-year annual rate: −32% (Biotechnology median +21%). Years of annual history on file: 10, FY2016 to FY2025, as filed.

DNTHDianthus Therapeutics, Inc.

Healthcare

$76.91+114% 1Y

$76.91

$32.9252 weeks$115.67

Is it growing?

Is DNTH growing?

Dianthus Therapeutics, Inc.'s revenue has shrunk 32% a year over three years.

−32%

Revenue growth, 3-year annual rate · Biotechnology median +21% · shrinking · compounded from fiscal-year columns as filed

Years of annual history on file: 10
Years of annual history on file · FY2016 to FY2025, as filed

Details›

Revenue FY2021: $1.5M
Revenue FY2022: $6.4M
Revenue FY2023: $2.8M
Revenue FY2024: $6.2M
Revenue FY2025: $2.0M

Annual income statements as filed with the SEC.

On our screens:Most shorted stocks

Biotechnology

Ranks #51 of 194 by RyuScore

Compare peers

EWTX-1.8%

Edgewise Therapeutics, Inc.

RLAY-0.90%

Relay Therapeutics, Inc.

TNGX-16%

Tango Therapeutics, Inc.

ARQT-3.0%

Arcutis Biotherapeutics, Inc.

TVTX-4.6%

Travere Therapeutics, Inc.

CRSP-1.2%

CRISPR Therapeutics AG